Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

(TBM) in adolescents and adults with or without HIV-infection in sub-Saharan Africa: Intensified TBM treatment with high-dose rifampicin and linezolid, compared to WHO standard TBM

  • 0 views
  • 24 Feb, 2021
  • 12 locations
Treatment Shortening of MDR-TB Using Existing and New Drugs

The purpose of this study is to compare the efficacy of a 'new treatment regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for nine or twelve months (investigational arm

fluoroquinolones
treatment regimen
pyrazinamide
linezolid
delamanid
  • 0 views
  • 22 Jan, 2021
  • 1 location
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of levofloxacin, linezolid, cycloserine and pyrazinamide (or clofazimine if resistant to

pulmonary tuberculosis
smear
linezolid
rifampin
pyrazinamide
  • 0 views
  • 24 Jan, 2021
  • 13 locations
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide treatments guided by PZA

  • 0 views
  • 29 Jan, 2021
  • 13 locations
The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance capacity to deliver effective treatment and care. According to the 2018 WHO TB Report, the overall treatment success rate of MDR-TB is 55% …

pulmonary tuberculosis
rifampin
sputum culture
isoniazid
chest x-ray
  • 0 views
  • 23 Jan, 2021
  • 20 locations
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient perspective in terms of their quality of life, shared decision making and satisfaction with services.

linezolid
clofazimine
bedaquiline
moxifloxacin
pretomanid
  • 0 views
  • 16 May, 2021
  • 6 locations
Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.

Primary objective of this pilot study is to evaluate the effect of recombinant human lactoferrin on the rate of infection with Clostridium difficile in long-term care patients supported by enteral feeding requiring broad spectrum antibiotics.

  • 1 views
  • 07 Nov, 2020
  • 1 location
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB) with fluoroquinolone resistance.

pulmonary tuberculosis
fluoroquinolones
linezolid
bedaquiline
vasectomy
  • 94 views
  • 25 Jan, 2021
  • 6 locations
Linezolid for Treatment of Nontuberculous Mycobacterial Diseases

A prospective open study to determine the efficacy and tolerability of oral linezolid 600mg./day for the treatment of 40 patients with nontuberculous mycobacterial diseases will be conducted at

  • 0 views
  • 24 Jan, 2021
  • 1 location
Pharmacokinetic Study of Linezolid for TB Meningitis

conversion in African pulmonary TB patients. Next to a higher dose of rifampicin, the approved antibacterial drug linezolid seems a good candidate for a new TBM regimen. The drug penetrates well into

  • 0 views
  • 06 May, 2021
  • 1 location